LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

Home・Stock List・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Closed

13.94 8.48

Buy Sell

Overview

Share price change

24h

Current

Min

12.79

Max

13.94

Key metrics
By Trading Economics
Income	-6.4M -20M
Sales	-807K 71M
EPS	-0.13
Profit margin	-28.24
Employees	624
EBITDA	-7.9M -14M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+55.63% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-282M 2B
Previous open	5.46
Previous close	13.94

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

8.81 / 10.18 Support & Resistance

Adaptive Biotechnologies Corp Chart

Past performance is not a reliable indicator of future results.

Related News

20 May 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 May 2026, 22:52 UTC

Major Market Movers

Osisko Shares Fall on Planned Convertible Notes Offering

20 May 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 May 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 May 2026, 23:44 UTC

Earnings

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 May 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 May 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 May 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 May 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 May 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 May 2026, 23:14 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 May 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 May 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 May 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 May 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 May 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 May 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 May 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 May 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 May 2026, 22:10 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 May 2026, 22:00 UTC

Earnings

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 May 2026, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 May 2026, 21:27 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 May 2026, 21:20 UTC

Earnings

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 May 2026, 21:19 UTC

Earnings

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 May 2026, 21:18 UTC

Earnings

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 May 2026, 21:17 UTC

Earnings

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 May 2026, 21:17 UTC

Earnings

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 May 2026, 21:17 UTC

Earnings

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 May 2026, 21:16 UTC

Earnings

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

55.63% upside

12 Months Forecast

Average 20.17 USD 55.63%

High 22 USD

Low 18 USD

Based on 8 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Adaptive Biotechnologies Corp - Dist in the past 3 months.

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.